Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07390890 · ClinicalTrials.gov registry record

DSLT for Reducing Medication in Glaucoma

A clinical trial of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by The Eye Institute of West Florida.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT07390890: Recruiting study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by The Eye Institute of West Florida.

NCT07390890 is a study of Ocular Hypertension and Primary Open Angle Glaucoma that is actively recruiting participants, run by The Eye Institute of West Florida. The registered enrollment target is 60 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07390890, a study of Ocular Hypertension and Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by The Eye Institute of West Florida.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Primary Outcome

The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.

Interventions

  • DEVICE Voyager DSLT

Study Locations (1)

Florida

  • The Eye Institute of West Florida - Largo

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-02-26
Est. Completion 2027-01-26

What NCT07390890 shows while recruiting

NCT07390890 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Voyager DSLT is the first listed.

NCT07390890 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07390890 about?

NCT07390890 is a clinical study titled "DSLT for Reducing Medication in Glaucoma". This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the ...

What is the current status of trial NCT07390890?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-02-26. Estimated completion is 2027-01-26.

What conditions does trial NCT07390890 study?

This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma.

What interventions are being tested in trial NCT07390890?

The interventions under investigation include: Voyager DSLT (DEVICE).

Who is sponsoring clinical trial NCT07390890?

This trial is sponsored by The Eye Institute of West Florida, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07390890 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ocular Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07390890's enrollment target sits among peer trials

60 43rd of 54 higher than 10 of 54 other Ocular Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07390890, the US trial registry maintained by the National Library of Medicine. NCT07390890 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.